Robert N Fried
CIK 1417952 · Chief Executive Officer · last filed 2026-07-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.30M
Companies
5
Total Filings
45
Lifetime Open-Market Net
$423.7K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NAGE | Chief Executive Officer | 1,072,833 | $3.08 | $3.30M | $0 | 4 | 2026-07-08 |
| Niagen Bioscience, Inc. (CDXC) Delisted | Chief Executive Officer | 1,067,315 | $7.87 | $8.40M | $423.7K | 28 | 2025-02-27 |
| Fluent, Inc. (IDI) Delisted | Director | 318,671 | — | — | $0 | 5 | 2016-06-03 |
| Fluent, Inc. (IDI.WS) Delisted | President & CEO | — | — | — | $0 | 2 | 2010-01-13 |
| Ideation Acquisition Corp. (IDI.U) Delisted | President & CEO | 620,500 | — | — | $0 | 1 | 2007-11-28 |
Recent Filings · Page 3 of 5
45 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-03-15 | Niagen Bioscience, Inc. (CDXC) Delisted | Mixed | +171,666 | $19.0K | EDGAR |
| 2019-02-22 | Niagen Bioscience, Inc. (CDXC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-11-09 | Niagen Bioscience, Inc. (CDXC) Delisted | Grant (A) | +166,667 | $0 | EDGAR |
| 2018-06-26 | Niagen Bioscience, Inc. (CDXC) Delisted | Grant (A) | +166,667 | $0 | EDGAR |
| 2018-05-16 | Niagen Bioscience, Inc. (CDXC) Delisted | Buy (P) | +10,000 | $36.3K | EDGAR |
| 2018-05-15 | Niagen Bioscience, Inc. (CDXC) Delisted | Grant (A) | +10,000 | $36.3K | EDGAR |
| 2018-01-23 | Niagen Bioscience, Inc. (CDXC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-12-21 | Niagen Bioscience, Inc. (CDXC) Delisted | Grant (A) | +333,333 | $0 | EDGAR |
| 2017-08-16 | Niagen Bioscience, Inc. (CDXC) Delisted | Buy (P) | +10,000 | $31.5K | EDGAR |
| 2017-04-17 | — | Grant (A) | +15,000 | $0 |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.